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NF-kB2 Genetic Variations are 
Significantly Associated with Non-
Small Cell Lung Cancer Risk and 
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During the last decade, a growing number of publications implicate NF-kB2 in NSCLC pathogenesis. 
Here, we investigated the clinical relevance of NF-kB2 single nucleotide polymorphisms (SNPs) 
rs7897947, rs11574852 and rs12769316 in NSCLC and their association with NF-kB2 protein and mRNA 
levels. Our data show that TT (rs7897947T >G) and AA (rs12769316G >A) genotypes were strongly 
associated with an increased risk for NSCLC (P = 0.019 and P = 0.003, respectively). Additionally, in 
multivariate analysis, TT (rs7897947T >G) homozygosity was associated with worse 2- and 3-year 
survival rates (P = 0.030 and P = 0.028, respectively), especially among patients with stages III/IV, who 
had worse 2, 3 and 5-year survival (P = 0.001, P = 0.022 and P = 0.035, respectively). In chemotherapy-
treated patients, TT (rs12769316G >A) homozygosity was also associated with worse 2- and 3-year 
survival compared to G allele carriers (P = 0.006 and P = 0.014, respectively). Furthermore, rs12769316 
was correlated with survival outcome of stage I and II patients (P = 0.031 and P = 0.006, respectively). 
Interestingly, amongst the patients who developed metastases, A allele carriers had better 5-year 
survival (P = 0.020). In addition, rs12769316 was associated with NF-kB2 protein (P = 0.001) and 
mRNA expression (P = 0.017) as well as with tumor maximum diameter (P = 0.025). Overall, this study 
suggests that rs7897947 and rs12769316 are involved in NSCLC susceptibility, in treatment response 
and in clinical outcome.
More than one million deaths per year are caused by lung cancer, making it the most frequently fatal cancer type 
in the western world1. Although current knowledge on the pathobiology of the disease has impressively expanded 
in the last decades, the survival rates of lung cancer patients have seen little improvement2,3. In the foreseeable 
future, the problem is expected to augment at a global level due to the increase in cigarette smoking, air pollution 
(indoor or outdoor) and occupational exposure to hazardous factors especially in less developed countries1,4. 
Non-small cell lung cancer (NSCLC) is the major histological subtype (adenocarcinomas, squamous cell carci-
nomas, large cell carcinomas) of epithelial lung malignancies, linked to about 80–85% of all lung cancer cases5.
Although a great variety of genes and signalling pathways have been implicated in the development and pro-
gression of human lung cancer, the role of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
has become an object of intense study in epithelial lung malignancies6–8 only in the last decade6–8. This transcrip-
tion factor has been characterized as a “double-edged sword” since, on the one hand, its role is important for the 
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immune response against cancer and on the other hand, under specific conditions, its activation can promote 
inflammation and tumor development9.
The NF-kB family consists of seven members [p105/p50 (NF-kB1), p100/p52 (NF-kB2), p65 (RelA), RelB, 
c-Rel], which are encoded by five genes (NF-kB1, NF-kB2, RELA, RELB, c-REL)10,11. NF-kB1 and NF-kB2 encode 
the precursor proteins p105 and p100. Subsequently, these molecules are proteasomally cleaved, leading to the 
production of functional proteins, p50 and p52, respectively11,12. The NF-kB family members constitute two dis-
tinct major signaling pathways, the “classical” and the “alternative”13. In the alternative pathway, two of the central 
players are p100/p52 and RelB, which together give rise to a transcriptionally active heterodimer (Fig. 1A).
Although the role of the classical pathway in the initiation and development of NSCLC has been well doc-
umented, the involvement of the alternative pathway of NF-kB has been described relatively recently14–17. Our 
group has shown that the transcription factor NF-kB (p100/p52) is overexpressed in NSCLC, with NF-kB2 
immunopositivity being associated with regional lymph node infiltration, tumor stage and tumor grade15.
Previous reports have documented the role of single nucleotide polymorphisms (SNPs) of NF-kB in a great 
variety of diseases18,19. In particular, genetic variations of critical components of the classical NF-kB pathway have 
been associated with an increased risk for cancer development, as well as with playing a significant role in the 
clinical outcome and patients’ response to treatment19–28. However, less is known about the role of NF-kB2 SNPs 
in cancer in general, and in lung cancer, in particular20,23,29. Recently, our group demonstrated a strong association 
of the tagging-SNP rs8100239 of the BCL3 (B-Cell Leukemia/Lymphoma 3) gene, a major transcriptional regu-
lator of the NF-kB pathway, with survival outcome of NSCLC patients14. This suggests an involvement of NF-KB 
family members’ SNPs in NSCLC pathobiology.
In this context, the aim of our study was to investigate the association of three NF-kB2 SNPs (Fig. 1B; 
rs7897947, rs11574852 and rs12769316) with NF-kB2 protein and mRNA levels, NSCLC risk and clinical 
outcomes of NSCLC patients. The selection was based on existing literature and tag SNP data obtained with 
internet-based tools. Rs12769316 is located on the promoter region of the NF-kB2 gene, while rs7897947 and 
rs11574852 are located on introns 8 and 20, respectively. To our knowledge, this is the first study whereby the role 
of genetic variations of NF-kB2 is being assessed in lung cancer.
Results
NF-kB2 SNP rs7897947 Was Associated With Increased NSCLC Risk. Genotype distributions for 
rs7897947 were significantly associated with the development of NSCLC. Although no difference was observed in 
allele specific frequencies between NSCLC patients and healthy controls, an increased risk for NSCLC was noted 
for the rs7897947 TT genotype compared to the G allele carriers (Table 1).
NF-kB2 SNP rs7897947 Was Associated With Overall Survival. Among all NSCLC cases, the rs7897947 TT 
homozygotes were associated with poorer OS compared to G allele carriers after two and three years of obser-
vation on univariate analysis with this effect being more prominent after the first 6 months of observation when 
the survival curves begin to separate (Table 2; Fig. 2A). Prognostic significance for 2- and 3-year OS persisted 
in multivariate analyses adjusted for age, sex, primary site, stage, and histological subtypes (Table 3). The same 
trend was also observed after 5 years of follow-up monitoring in both univariate and multivariate analyses, albeit 
without reaching statistical significance (Tables 2 and 3).
Further analysis by stage stratification revealed a prognostic value for the rs7897947 for 2-, 3- and also 5-year 
survival for patients of stages III and IV (P = 0.001; HR, 2.271; 95% CI, 1.358–3.799, P = 0.022; HR, 1.629; 95% 
CI, 1.056–2.514 and P = 0.035; HR, 1.551; 95% CI, 1.019–2.361, respectively). In particular, the prognosis of the 
TT patients was worse compared to the G allele carriers (Fig. 2B). In contrast, survival of stage I or II patients was 
unaffected by rs7897947 (P = 0.624; HR, 0.851; 95% CI, 0.444–1.631 and P = 0.109; HR, 1.702; 95% CI, 0.874–
3.313 for the 5-years OS).
Moreover, the TT genotype was correlated with a worse 2- and 3-year OS, compared to the presence of the 
G allele in 79 patients who developed metastases in liver, brain, bones and/or adrenals although significance 
remained for the 2-year OS after FDR analysis and was marginally lost for the 3-year survival (Fig. 2C; P = 0.012; 
HR, 2.234; 95% CI, 1.192–4.187 and P = 0.040; HR, 1.729; 95% CI, 1.024–2.918, respectively). Although the same 
trend was observed for 5-year survival, the results did not reach statistical significance (P = 0.134; HR, 1.450; 95% 
CI, 0.892–2.355).
Significance Of SNP Rs7897947 In Clinical Outcome Of Chemotherapy-Treated Patients. SNP rs7897947 was also 
associated with the OS of patients who received first-line chemotherapy (n = 69) independently of the disease 
stage. In particular, patients with the TT genotype displayed worse 2- and 3-year survival rates than G allele 
carriers which persisted after FDR analysis (Fig. 2D; P = 0.006; HR, 2.576; 95% CI, 1.309–5.068, q = 0.018 and 
P = 0.014; HR, 2.064; 95% CI, 1.161–3.668, q = 0.021 respectively). A similar trend was also detected for 5-year 
OS, but was not statistically significant (Fig. 2D, P = 0.093; HR, 1.566; 95% CI, 0.928–2.643).
Correlations Of SNP Rs7897947 With Clinicopathological Parameters. SNP rs7897947 was not associated with 
disease stage at presentation (P = 0.519) and smoking history was similar between stages I and II and stages III 
and IV (P = 0.978). Moreoever, rs7897947 genotype was not associated with age, gender, primary location, his-
tological subtype, grade, maximum diameter, lymph node infiltration, regional relapse or metastatic progression 
(see Supplementary Table S1). In addition, rs7897947 genotypes (either dominant or recessive model) were not 
associated with cytoplasmic (P = 0.991 and P = 0.608, respectively) or nuclear protein expression (P = 0.801 and 
P = 0.943, respectively) or mRNA expression levels (P = 0.486 and P = 0.393, respectively).
www.nature.com/scientificreports/
3SCIENTIfIC RepoRts |  (2018) 8:5259  | DOI:10.1038/s41598-018-23324-3
NF-kB2 SNP Rs12769316 Was Associated With NSCLC Risk. Although genotype frequencies for 
rs12769316 were in equilibrium for healthy controls, deviations from the Hardy-Weinberg model were found for 
NSCLC patients (P = 0.8159 and P = 0.0003, respectively). An increased risk of NSCLC was associated with the 
rs12769316 minor allele A (Table 1) and in particular the homozygous genotype AA compared to the AG and GG 
genotypes (Table 1).
Figure 1. (A) Schematic diagram of the alternative pathway of NF-kB (Reprinted from Lung Cancer, 89, 3, 
Dimitrakopoulos et al., 311–319, Variant of BCL3 gene is strongly associated with five-year survival of non-
small-cell lung cancer patients, 2015, with permission from Elsevier). (B) Genomic positions of studied SNPs in 
NF-kB2 gene. (C) The study design outline. Abbreviations: BAFFR; tumor necrosis factor receptor superfamily 
member 13 C, CD40; CD40 molecule, TNF receptor superfamily member 5, LTβR; Lymphotoxin Beta Receptor 
(TNFR Superfamily, Member 3), RANK; Receptor Activator Of Nuclear Factor-Kappa B, NIK; NF-Kappa-
Beta-Inducing Kinase, IKKα; IκB Kinase α, p100; nuclear factor NF-kappa-B p100 subunit, p52; nuclear factor 
NF-kappa-B p52 subunit, RELB; Transcription factor RelB, BCL3; B-Cell CLL/Lymphoma 3, FBXL15; F-Box 
and Leucine-Rich Repeat Protein 15, GBF1; Golgi Brefeldin A Resistant Guanine Nucleotide Exchange Factor 1, 
NF-kB2; nuclear factor-kappa B2, RPARP-AS1; RPARP antisense RNA 1.
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SNP Rs12769316 And Survival Of Stage I or II NSCLC Patients. Rs12769316 genotypes were not associated 
with 2-, 3- and 5-year survival (P = 0.632; HR, 1.101; P = 0.967; HR, 0.993 and P = 0.513; HR, 0.896, respec-
tively). However, when stage was taken into consideration, associations between survival of stage I or II patients 
and rs12769316 were observed (Fig. 3A,B), which persisted upon FDR correction. Particularly, the A allele was 
related to a worse 3-year survival in stage I patients in both univariate and multivariate (adjusting for age, sex, 
primary site and histological subtype) analysis (P = 0.031; HR, 2.426; 95% CI, 1.050–5.603 and P = 0.047; HR, 
2.353; 95% CI, 1.012- 5.467, respectively). On the contrary, stage II G homozygotes displayed a worse 5-year 
survival compared to A allele carriers in univariate analysis (P = 0.006; HR, 3.049; 95% CI, 1.298–7.165) and in 
multivariate analysis (P = 0.029; HR, 3.022; 95% CI, 1.117–8.17), whereas OS of stage III and IV patients was 
unaffected by rs12769316 (Fig. 3C,D, P = 0.687; HR, 1.116; 95% CI, 0.646–1.929 and P = 0.874; HR, 1.072; 95% 
CI, 0.439–2.617).
Among the patients who received first-line chemotherapy (n = 67), independent of the disease stage, a 
trend was noted between the rs12769316 genotypes and 5-year OS, but was not statistically significant (Fig. 3E, 
P = 0.062; HR, 0.600; 95% CI, 0.345–1.043). Additionally, amongst patients who developed liver, brain, bone and 
adrenal gland metastases, A allele carriers had better 5-year survival compared to G homozygotes even after FDR 
analysis (Fig. 3F, P = 0.020; HR, 0.548; 95% CI, 0.324–0.925).
SNP Rs12769316 Was Associated With NF-kB2 Expression. Cytoplasmic but not nuclear NF-kB2 protein levels 
were associated with the presence of rs12769316 with G allele carriers having higher cytoplasmic expression than 
AA homozygotes (Supplementary Figure S1A, P = 0.048). In addition, GG homozygotes were found to have lower 
NF-kB2 mRNA levels compared to A allele carriers (Supplementary Figure S1B, P = 0.008).
NF-kB2 SNP rs12769316 Was Associated With Disease Stage And Tumor Maximum Diameter. According to 
the dominant model for allele A, rs12769316 was associated with disease stage (P = 0.037) with G homozygosity 
being correlated with a higher frequency of metastatic disease (stage IV) compared to A allele carriers (P = 0.010).
In addition, rs12769316 genotypes were associated with the maximum diameter of the primary tumor lesions. 
Using a three-tier system (≤3.5 cm vs >3.5 cm to ≤6.0 cm vs >6.0 cm), NSCLC patients with tumors bigger than 
6 cm maximum diameter were more frequently heterozygotes (P = 0.025).
SNP Counts χ2 Univariate analysisb
Genotype
Cases
n (%)
Controls
n (%) Pa P OR (95% CI)
Total 268 279 — — —
rs7897947 264 279 — — —
ΤΤ 145 (54,9) 125 (44,8)
0.052
— 1.000
GT 89 (33,7) 120 (43,0) 0.016 0.639 (0.444–0.920)
GG 30 (11,4) 34 (12,2) 0.326 0.761 (0.441–1.313)
ΤΤ + GΤ 
vs
GG
234 (88,6)
30 (11,4)
245 (87,8)
34 (12,2) 0.766 1.082 (0.642–1.825)
ΤΤ vs
GT + GG
145 (54,9)
119 (45,1)
125 (44,8)
154 (55,2) 0.019 1.501 (1.070–2.106)
T allele 379 (71.8) 370 (66.3)
0.051 0.052
1.292 (0.998–1.673)
G allele 149 (28.2) 188 (33.7) 0.774 (0.598–1.002)
rs12769316 242 278 — — —
AA 20 (8.3) 7 (2.5)
0.012
1.000
AG 62 (25.6) 71 (25.5) 0.005 0.280 (0.116–0.679)
GG 160 (66.1) 200 (71.9) 0.012 0.306 (0.121–0.771)
AA + AG vs
GG
82 (33.9)
160 (66.1)
78 (28.1)
200 (71.9) 0.151 1.314 (0.905–1.909)
AA vs
AG + GG
20 (8.3)
222 (91.7)
7 (2.5)
271 (97.5) 0.005 3.488 (1.448–8.399)
A allele 102 (21.1) 85 (15.3)
0.015
0.016 1.480 (1.077–2.033)
G allele 382 (78.9) 471 (84.7) 0.676 (0.492–0.929)
rs11574852 261 278 — — —
AA 239 (91.6%) 254 (91.4%)
0.624
— 1.000
AC 22 (8.4%) 23 (8.3%) 0.999 0.984 (0.534–1.812)
CC 0 (0.0%) 1 (0.4%) — —
A allele 0,9579 0,9585
0.821 0.821
1.070 (0.596–1.922)
C allele 0,0421 0,0415 0.935 (0.520–1.679)
Table 1. ORs and 95% CIs for NSCLC in relation to genotypes of studied NF-kB2 SNPs. aP derives from the χ2 
test and refers to overall association of genotypes with NSCLC risk. bP, OR and 95% CI derived from logistic 
regression analysis. Abbreviations: CI, confidence interval; OR, odds ratios.
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Rs12769316 was independent of age, gender, primary location, histological subtype, grade, lymph node infil-
tration, smoking history and relapse rate (see Supplementary Table S2). A statistically significant association was 
noted between rs12769316 and the development of brain metastases (P = 0.048), which, however, requires further 
evaluation due to the small number of patients in each genotypic subgroup.
Rs11574852 Was Associated With Age And Regional Relapse. Rs11574852 was associated with 
age and regional relapse (P = 0.038 and P = 0.013, respectively) (see Supplementary Table S3). No significant 
correlation was found between rs11574852 and NSCLC risk, gender, primary location, histological subtype, 
grade, lymph node infiltration, maximum diameter, regional relapse or metastasis development (Table S3). 
Additionally, no relation was found between this SNP, cytoplasmic (P = 0.191) or nuclear NF-kB2 protein expres-
sion (P = 0.857) as well as mRNA levels (P = 0.222).
SNP
Base 
change
Univariate analysis
2-year OS
Log-rank P
HR, 95% CI
Univariate analysis
3-year OS
Log-rank P
HR, 95% CI
Univariate analysis
5-year OS
Log-rank P
HR, 95% CI
Rs number
ancestral 
>derived General Dominant Recessive General Dominant Recessive General Dominant Recessive
rs7897947 T > G 0.030—
0.013
1.618 (1.102–2.377)
0.894
1.041 (0.572–1.893)
0.102
—
0.033
1.428 (1.023–1.994)
0.357
1.314 (0.728–2.372)
0.163
—
0.062
1.329 (0.981–1.801)
0.294
1.323 (0.778–2.247)
rs12769316 G > A 0.891—
0.632
1.101 (0.738–1.644)
0.866
1.060 (0.535–2.099)
0.992
—
0.967
0.993 (0.696–1.416)
0.900
0.962 (0.519–1.781)
0.682
—
0.513
1.116 (0.800–1.557)
0.421
0.781 (0.423–1.440)
rs11574852 A > C 0.335— — —
0.961
— — —
0.750
— — —
Table 2. Univariate analysis of dominant and recessive models of rs7897947, rs12769316 and rs11574852 
with the OS of NSCLC patients. Rs7897947 dominant: TTvsGT + GG; rs7897947 recessive: TT + GTvsGG; 
rs12769316 dominant: AA + GAvsGG; rs12769316 recessive; AAvsGA + GG.
Figure 2. Overall survival (OS) and rs7897947 genotypes. Kaplan-Meier plot of OS according to the dominant 
model for the variant allele (G). (A) all patients, (B) patients of stage 3 and 4, (C) patients who developed 
metastatic disease in brain, bones, adrenals and liver, (D) patients who received chemotherapy.
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Discussion
Over the last decades, a progressive understanding of the molecular biological mechanisms behind NSCLC devel-
opment has led to the realization that NSCLC should no longer be considered only as a single, uniform disease 
but rather as a heterogeneous entity30. It is therefore imperative to focus on a more precise and personalized treat-
ment management of NSCLC patients in order to improve significantly the response to treatment and thus the 
survival outcome31. In this vein, the SNP profile of specific genes can be potentially used not only for identifying 
high-risk individuals, but also for predicting response to therapy and survival outcome, aiming to achieve a more 
personalized treatment approach14,32.
In this study, three SNPS of the NF-kB2 gene were evaluated in NSCLC patients and healthy controls through 
monitoring of their association with NF-kB2 expression, clinicopathological parameters and clinical outcome of 
the patients. Two of these (rs12769316 and rs7897947) appear to have a role in NSCLC.
Rs12769316 was found to be associated with NF-kB2 protein and mRNA expression which could be justi-
fied by its location, upstream of the NF-kB2 transcription start site and on the promoter region of the NF-kB2 
gene, within a binding site for the CCCTC-binding transcription factor (CTCF)33. In addition, the internet-based 
PROMO software predicted more transcription factor binding sites in the genomic region of rs1276931634. The 
possible functional role of rs12769316 in the transcriptional regulation of NF-kB2 gene was also predicted from 
the internet-based bioinformatic tool F-SNP35. The second polymorphism (rs7897947) was not related to NF-kB2 
protein and mRNA expression although was related to other aspects of NSCLC as is discussed below. It is located 
on the 8th intron of the NF-kB2 gene, but nothing is known regarding its possible function. The web-based tool 
SNPinfo indicated a lack of association of this SNP with splicing or a possible miRNA binding site36. On the other 
hand, using the variant effect predictor (VEP), we noted that rs7897947 was located on the non-coding RNA 
transcript ENST00000467116 which retains intron 8 and through which it is possible to function37.
Our study further revealed an association of rs12769316 and rs7897947 with NSCLC risk. Notably, minor 
allele A of rs12769316 and homozygotes TT of rs7897947 were associated with a higher risk of NSCLC 
development. The role of these two SNPs has also been studied in hematological malignancies, especially in 
bortezomib-based treatment of patients with multiple myeloma where disease development was independent of 
rs7897947 while a trend was noted for an association with rs1276931629.
Another intriguing finding of the present study is the correlation of rs7897947 and rs12769316 with OS. 
Notably, OS was significantly better for rs7897947 G allele carriers, especially for stages III and IV patients com-
pared to homozygotes TT, which persisted after FDR corrections. This observation in conjunction with the 
association of rs7897947 with the OS of patients receiving first-line chemotherapy and with the development of 
distant metastases may be indicative of its role in systemic treatment. However the association of rs7897947 with 
a higher risk of NSCLC possibly reflects a more fundamental and pivotal role of this SNP in disease initiation and 
progression. Supportive to this is also our observation that the T allele frequency was higher in stages III and IV 
compared to stages I and II.
Interestingly, rs12769316 was also associated with OS. Notably, the presence of the A allele of rs12769316 was 
related to decreased OS rates, especially for stage I patients whereas surprisingly the opposite was noted for stage 
II patients. The association of rs12769316 with OS is also compatible with the correlation of this SNP with the risk 
of NSCLC development. This is not the first time that this SNP has been related to the OS of patients. Presence of 
the A allele has been associated with a superior OS in multiple myeloma patients treated with bortezomib-based 
regimens29. The observed differences in clinical outcome when we take into account the rs12769316 genotype, 
the stage and the treatment or not with first-line chemotherapy support further our notion that rs12769316 may 
interplay with therapeutic choices.
The possible mechanisms through which rs7897947 and rs12769316 could be implicated in NSCLC patho-
genesis have not been studied with the effects of both SNPs at the molecular level remaining unknown. We have 
recently reported that another polymorphism (BCL3 rs8100239) in the alternative pathway of NF-kB is associated 
with survival of NSCLC patients14, which together with the current findings perhaps suggest that SNPs in genes 
of this pathway infer the importance of this pathway in cancer and may have a role in lung cancer pathogenesis 
and/or in response to therapy.
Polymorhism Base change
Multivariate analysis
2-year OS
Multivariate analysis
3-year OS
Multivariate analysis
5-year OS
HR
(95% CI)
Cox proportional
Hazard models
P
HR
(95% CI)
Cox proportional
Hazard models
P
HR
(95% CI)
Cox proportional
Hazard models
P
rs7897947
dominant (TTvsGT + GG)
recessive (TT + GTvsGG)
T > G
1.591
(1.045–2.423)
0.826
(0.419–1.630)
0.030
0.582
1.503
(1.044–2.165)
1.147
(0.590–2.231)
0.028
0.685
1.360
(0.977–1.893)
1.202
(0.669–2.161)
0.069
0.538
rs12769316
dominant (AA + GAvsGG)
recessive (AAvsGA + GG)
G > A
1.195
(0.773–1.849)
1.391
(0.689–2.808)
0.423
0.358
1.103
(0.750–1.622)
1.324
(0.702–2.495)
0.618
0.386
0.974
(0.678–1.400)
1.025
(0.548–1.919)
0.887
0.937
rs11574852
(AAvsAC) A > C
1.484
(0.645–3.411) 0.353
0.849
(0.604–2.126) 0.609
1.041
(0.558–1.942) 0.899
Table 3. Multivariate analysis of OS of NSCLC patients according to genotypes of polymorphisms rs7897947, 
rs12769316 and rs11574852. Covariates: Age, sex, primary site, stage, histological subtype.
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Despite the promising results of our study, we must acknowledge some weak points. A major limitation of our 
study is that retrospectively collected samples (Group R) include mainly surgical specimens and therefore early 
stage lung cancer cases, whereas in Group P cases are almost equally distributed in the different stages. In order 
to minimize the effect of this point we have performed analyses not only in Group R and in Group P, but also in 
Group PR (analysis based on combined groups P and R) without detecting significant differences to sub-analyses. 
Another weak point is that immunohistochemistry was performed in a cohort almost similar to Group R, with a 
few stage IV cases, mainly due to the limitations in tissue availability. Larger cohorts and ideally an independent 
validation group would be a logical next step in order to achieve more robust conclusions.
In conclusion, we report for the first time that two (rs7897947 and rs12769316) of the three studied genetic 
variants of the NF-kB2 are associated with increased risk and decreased OS outcome of patients with NSCLC. 
These findings further support our previous work regarding the role of the alternative pathway of NF-kB in 
Figure 3. Overall survival (OS) and rs12769316 genotypes. Kaplan-Meier plot of OS of NSCLC patients 
according to the dominant model for the A allele. (A) Stage I patients, (B) stage II patients, (C) stage III patients, 
(D) stage IV patients, (E) patients who received first-line chemotherapy, (F) patients who developed metastases 
(brain, liver, bones, adrenals).
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NSCLC15. Functional studies will shed light on the molecular mechanisms through which these SNPs can affect 
the development and therapeutic response of NSCLC.
Methods
Study Design, Population and Data Collection. This study was approved by the Committee on 
Research and Ethics as well as the Scientific Committee of the University Hospital of Patras, Greece and was 
designed according to the ethical guidelines of the Helsinki Declaration (2013)38. The participants took part vol-
untarily with written informed consents obtained from all.
To perform the present study, we used a two-stage design in order to assess SNPs in relation to clinicopatho-
logical data, therapeutic choices, and clinical outcome (Fig. 1C). Firstly, three SNPs were evaluated in the NF-kB2 
gene region (rs7897947, rs11574852, rs12769316) in a retrospectively-collected group, followed by validation of 
our preliminary results in a second prospectively collected patient cohort, with a statistical analysis performed in 
each subgroup. In order to enhance the association and to achieve more robust statistical results, we performed a 
meta-analysis of the retrospectively and prospectively groups, the results of which are presented here.
Clinicopathological data, disease outcome, and vital status after a 60 month observation period were obtained 
from pathology reports, from medical records or through direct communication with the patients. Characteristics 
of the study population and relevant clinicopathological information are included in Supplementary Table S4.
A total cohort of 272 previously untreated patients of all ages with histopathologically or cytologically con-
firmed NSCLC (squamous carcinoma or adenocarcinoma or large cell carcinoma) was enrolled for this study. 
For the retrospectively collected group (Group R), 148 tumor-adjacent, non-malignant and macroscopically nor-
mal tissue specimens were retrospectively collected from the archives of the Department of Pathology of the 
University Hospital of Patras, Greece. Additionally, peripheral blood samples were prospectively collected from 
2008 to 2010 from 124 newly diagnosed NSCLC patients (Group P). All cases were diagnosed and medically 
managed at the Division of Medical Oncology and the Department of Cardiothoracic Surgery at the University 
Hospital of Patras between 2004 and 2015. Standard-of-care treatment options were applied to all patients of the 
study according to the disease stage, the comorbidities, and the performance status following the current treat-
ment guidelines. As case-exclusion criteria from our study, we considered the uncertain histology, the non-Greek 
Caucasian ethnic origin and the previous cancer-related therapeutic managements.
During the same period, peripheral blood specimens from 279 healthy control donors (Group H) were col-
lected in the context of annual medical check-up. Groups of controls and patients were age- and sex-matched 
(Supplementary Table S5). The similarity of the genetic backgrounds was ensured by recruiting only persons with 
Greek Caucasian origin. Exclusion criteria included cancer- or any disease-related medical history and cancer 
family history and known gene mutations which predispose to cancer. The same cohort was used in a previous 
association study, the results of which were recently published14.
Selection Οf SNPs. Literature (PubMed, Google Scholar) was reviewed by using suitable keywords (SNPs, 
NF-kB2, cancer, NSCLC, lung cancer, risk factor) for the selection of particular SNPs found within the NF-kB2 
gene that had been previously assessed regarding their role in cancer. SNP rs12769316 had been found to be cor-
related with overall survival (OS) of patients with multiple myeloma29. In addition, tagging SNPs rs7897947 and 
rs11574852 were selected through the use of the internet-based tools “Tagger” and “SySNPs for the CEU popula-
tion39,40. The cut-off for minor allele frequency was determined at 5% and the coefficient of determination r2 = 0.8 
was captured. Genomic location, minor allele frequencies (MAF) and other specific characteristics of SNPs are 
presented in Supplementary Table S6.
DNA Isolation. Genomic DNA was extracted from whole blood samples of 124 cancer patients (Group P) 
and 279 healthy donors (Group H) using the commercial kit “QIAmp mini blood kit” (QIAGEN Ltd., Crawley, 
UK). Furthermore, DNA was also isolated from 148 FFPE, tumor adjacent, non-malignant tissue specimens 
(Group R) using the “QIAamp DNA FFPE Tissue kit” (QIAGEN Ltd., Crawley, UK). DNA was stored at −20 °C 
until required.
Genotyping. Genotyping was performed for the selected polymorphisms, blinded to the case status, by a 
real-time PCR technique, on the basis of detection differences in the melting temperatures of the products (Tm) as 
described by Wang et al.41. A GC-tail was introduced at the end of one of the two allele-specific primers that we 
designed, making the discrimination of alleles feasible by producing differences in amplicon Tm, further identified 
using SYBR Green I and melting curve analysis. Real-time PCRs were performed using a MX3000p PCR cycler 
(Stratagene, La Jolla, CA, USA). Primers were tested for specificity with BLAST (http://blast.ncbi.nlm.nih.gov/) 
and synthesized by VBC-GENOMICS Bioscience Research GmbH (Vienna, Austria). Reactions were performed 
in duplicate using the KAPA SYBR FAST Master Mix (KAPA BIOSYSTEMS, Woburn, MA, USA). No template 
controls were included in each PCR reaction. PCR conditions, primers sequences and relative concentrations are 
available upon request.
Sequencing. Due to the observed deviation from the Hardy-Weinberg Equilibrium (HWE) of the cancer 
patients genotypes and in order for the results of the melting temperature (Tm)-shift SNP genotyping analysis to 
be confirmed, further validation was achieved through sequencing of several samples, representative of all three 
genotypes. The sequences of the primers and PCR conditions that we used for sequencing can also be provided 
upon request. Sequencing was performed at Cemia SA (University of Thessaly, Greece). All obtained sequences 
were in agreement with our genotyping results.
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Immunohistochemical Analysis. Immunohistochemical staining of NF-kB2 was assessed in 151 NSCLC 
tumor samples (see Supplementary Table S7) and representative, tumor-adjacent, normal tissue specimens, fol-
lowing standard streptavidin-biotin-peroxidase complex procedures. These samples were selected based on avail-
ability of full clinical information and adequacy of tissue specimen. Four μm sections from FFPE samples were 
deparaffinised in xylene and rehydrated in a series of graded alcohols. Next, the sections were pre-treated in a 
microwave oven and peroxidase activity was blocked with 3% hydrogen peroxide for 20 min, followed by incuba-
tion with an appropriate protein blocking solution. A mouse monoclonal anti-NF-kΒ2 antibody (dilution 1:500, 
clone: C-5 sc-7386, Santa Cruz, USA) was used as the primary antibody. Detection was performed using the 
Envision detection kit (Dako Cytomation Co., Glostrup, Denmark) according to the manufacturer’s instructions. 
Diaminobenzidine (DAB) was used as the chromogen for visualization. Sections were counterstained with Harris’ 
hematoxylin solution, dehydrated and mounted. To test the specificity, the procedure was repeated in consecutive 
sections, substituting the anti-NF-kB2 antibodies with protein blocking solution.
Evaluation Of Immunohistochemistry. For the evaluation of the stained slides the same procedure was 
followed as previously described15. One pathologist (H.P.) and one investigator (F.D.) assessed all slides inde-
pendently, blinded to the case. Histological type and tumor grade were confirmed according to the 2004 WHO 
classification of lung tumours42. The intensity and distribution of the NF-kB2 signal were the parameters used to 
estimate NF-kB2 expression. The total score for each slide was calculated as the sum of intensity (0–3) and distri-
bution (0–3), forming a semiquantitative scoring system (between 0 and 6). Cases with staining in >10% of cells 
were considered positive. Using the 33rd and 66th percentiles as cut-offs, NF-kB2 expression in cancer cells was 
categorized into three groups (high vs. medium vs. low). For each tissue section, the more representative areas 
were selected using low-power fields (magnification 10x). Accurate quantification was performed on high power 
fields (magnification 40x).
Gene expression analysis of NF-kB2 by Quantitative Real-Time PCR (qRT-PCR). By qRT-PCR, 
we measured NF-kB2 gene expression. RNA isolation from 59 patients was performed using the commercially 
available kit NucleoSpin® totalRNA FFPE Kit (MACHEREY-NAGEL, GmbH & Co., Düren Germany) fol-
lowed by reverse transcription and cDNA synthesis based on SuperScript III First-Strand Synthesis System (Life 
Technologies, Carlsbad, CA, USA) according to the protocol. Specific primers for NF-kB2 and IPO8 (Importin 8, 
used as a reference gene) genes were designed using OligoAnalyzer 3.1 according to the sequences given in NCBI 
(http://www.ncbi.nlm.nih.gov/). Primers were synthesized by IDT. Both primer sequences as well as reaction 
conditions will be provided upon request. The PCRs were performed in triplicate in an MX3000p (Stratagene, La 
Jolla, CA, USA) cycler. LinRegPCR software was used in order to quantify detected signals and normalize them 
to the levels of IPO843.
Statistical Analysis. In order to test the deviation of our population from the HWE, a standard χ2-test was 
used. Differences in the distribution of genotypes between patients and healthy controls were also calculated using 
the χ2 test. To evaluate associations between genotypes and NSCLC susceptibility, logistic regression and odds ratios 
(ORs) were used based on an unconditional model. Possible associations between genotypes and clinicopathological 
parameters of the tumors or expression were evaluated using the Kruskal-Wallis or the Mann-Whitney tests for ordi-
nal variables, χ2 test for nominal variables, and T test for continuous variables. In some cases, to assess the possible 
relations between genotypes and NF-kB2 expression, a logistic regression analysis was performed.
Overall survival time was determined as time from the date of surgery or from the date of histological or cyto-
logical diagnosis until the date of confirmed death or last follow-up. Univariate analysis was performed estimat-
ing survival rates with the Kaplan–Meier method and then compared with the log-rank test. Cox Proportional 
Hazards models and Hazard Ratios (HRs) were calculated in order for a multivariate survival analysis to be con-
ducted using age, sex, primary site, disease stage and histological subtype as co-factors. False discovery rate (FDR) 
analysis was performed using the excel spreadsheet calculator available at the Handbook of Biological Statistics by 
John H. McDonald (http://www.biostathandbook.com/multiplecomparisons.html). Statistical significance per-
sisted after FDR analysis for all P values < 0.05 reported, unless otherwise indicated in the text. Statistical analyses 
were performed using the IBM SPSS Statistics software for Windows, Version 21.0 (Armonk, NY: IBM Corp). For 
all comparisons, statistical significance was defined as P < 0.05 and all statistical tests were two-sided.
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